Drug Target Review

SEPTEMBER 20, 2023

“AI will not replace drug discovery scientists, but drug discovery scientists who use AI will replace those who don’t” – comment during EFMC meeting 2018 Progressing a drug molecule from concept to commercialisation typically takes 10-15 years and has high associated costs of up to $2 billion per launched drug, if all failures are factored in.

Drugs 105

Drugs Metabolic Stability Computational Chemistry Pharmaceuticals 105

Eye on FDA

AUGUST 2, 2022

And since 2014 the Office of Prescription Drug Promotion (OPDP) has broken double digits only 3 times, producing only 6 letters in both 2020 an 2021. That is particularly true since we have a new FDA Commissioner, a new head of the Center for Drug Evaluation and Research (CDER), and a new head of OPDP.

Pharmaceutical Companies 88

Pharmaceutical Companies FDA Pharmaceuticals Drugs 88

Practical Cheminformatics

JANUARY 8, 2024

Picking up where we left off in Part I , this post covers several other ML in drug discovery topics that interested me in 2023. Most of the LLM activity in the drug discovery space in 2023 was reported as preprints from academic groups. Most of the drug discovery examples were underwhelming. Here’s the structure of Part II.

Drugs 136

Drugs Small Molecule Bioinformatics Packaging 136

Drug Target Review

OCTOBER 5, 2023

The first instance of aHSCT in this cohort dates to 2004, and the average age of these patients at the time of treatment was 31, with a majority of them being women, accounting for 64 percent of the group. Around three years following their aHSCT, 20 patients (11 percent) were administered disease-modifying drugs.

Therapies 116

Therapies Treatment Clinical Trials Disease 116

Common Sense for Drug Policy Blog

OCTOBER 22, 2024

Injection-Related Injuries in People Who Inject Drugs: Skin and Soft Tissue Infection, Vascular Damage, and Wounds "Common SSTIs include cellulitis ( Figure 1 ) and skin abscesses ( Figure 2 ), 5 and SSTI is common in PWIDs. The number of injection-related admissions increased 33% per year from 1997 and 1998 through 2003 and 2004.

Hospitals 52

Hospitals Drugs 52

NIOSH Science Blog: Drugs

SEPTEMBER 25, 2024

When the Nanotechnology Research Center (NTRC) first began in 2004, one of its biggest challenges was understanding exactly what to measure and how Although this change makes the materials useful for creating new products that benefit society, their small size presents challenges to protecting worker safety and health.

Research 52

Research Engineering Science Production 52

FDA Law Blog: Biosimilars

SEPTEMBER 23, 2024

Hatch Foundation’s For cheap generic drug prices, you can thank 40 years of Hatch-Waxman We Work For Health’s Hatch-Waxman Act: Celebrating 40 Years of a Balanced and Innovative Drug Ecosystem Tradeoffs’ Race to the Bottom Series FDA CDER Conversations – 40th Anniversary of the Generic Drug Approval Pathway The U.S.

FDA 59

FDA Drugs International Pharmaceuticals 59

NIOSH Science Blog: Drugs

FEBRUARY 1, 2024

The National Institute for Occupational Safety and Health (NIOSH) Nanotechnology Research Center (NTRC) has taken on a global leadership role on research and guidance for nanomaterials in the workplace since the formation of NTRC in 2004 [1].

International 55

International Research 55

National Institute on Drug Abuse: Nora's Blog

MARCH 6, 2025

Advancing reduction of drug use as an endpoint in addiction treatment trials astewart Thu, 03/06/2025 - 09:59 Nora's Blog March 18, 2025 Image Getty Images/ SolStock This blog was also published in the American Society of Addiction Medicine (ASAM) Weekly on March 18, 2025.&

Treatment 69

Treatment Trials Clinical Trials Drugs 69

Common Sense for Drug Policy Blog

FEBRUARY 22, 2024

Brain Disease Model of Addiction "In 1997, Alan Leshner, the Director of the US National Institute on Drug Abuse (NIDA), proclaimed that addiction was a chronic, relapsing, brain disease ( Leshner, 1997 ). Drug Alcohol Depend. dwf_admin Thu, 02/22/2024 - 11:04 Source Hall W, Gartner C, Morphett K. 2023;253:111033. 2023.111033

Disease 52

Disease Treatment Drugs 52

NIH Director's Blog: Drug Development

OCTOBER 27, 2020

Science, 2020 One way to fight COVID-19 is with drugs that directly target SARS-CoV-2, the novel coronavirus that causes the disease. That’s the strategy employed by remdesivir , the only antiviral drug currently authorized by the U.S. Food and Drug Administration to treat COVID-19. Credit: DE Gordon et al.,

Drug Development 52

Drug Development Drugs Virus Science 52

Sygnature Discovery

OCTOBER 10, 2023

On 10th October 2023, Sygnature Discovery, a world-leading integrated drug discovery provider and non-clinical solutions provider, has announced a scientific collaboration with human induced pluripotent stem cell (iPSC) experts, Axol Bioscience.

Small Molecule 52

Small Molecule Drugs Disease Clinical Trials 52

NIH Director's Blog: Drug Development

OCTOBER 11, 2022

Not only has click chemistry expanded our ability to explore the molecular underpinnings of a wide range of biological processes, but it has provided us with new tools for developing drugs, diagnostics, and a wide array of “smart” materials. 2004 Jul;11(7):1009-1016. Kolb, HC, Finn, MG, Sharpless, KB. 2002, 67 (9), 3057–3064. [4]

Research 52

Research Small Molecule Science Clinical Research 52

PLOS: DNA Science

MARCH 28, 2024

A new drug has entered the arsenal against Duchenne muscular dystrophy (DMD), a genetic disease that affects boys and is challenging to treat. These drugs affect which parts of specific genes are transcribed and translated into protein, and which parts are shielded – aka gene expression. Hyperbole or Hope?

FDA Approval 96

FDA Approval Treatment FDA DNA 96

Sygnature Discovery

JULY 31, 2023

Leading integrated drug discovery partner, Sygnature Discovery (“Sygnature”) has announced its acquisition of one of North America’s largest discovery Contract Research Organisations, Canada-based NuChem Sciences. Previous acquisitions made were Peak Proteins in April 2022 and SB Drug Discovery in January 2023. Marc Lebel, Pharm.

Computational Chemistry 52

Computational Chemistry Science Clinical Trials Pharmaceutical Companies 52

Broad Institute

AUGUST 27, 2024

billion, over 8 years TESARO had built a robust pipeline of products and drug candidates, had received multiple drug approvals, was commercializing medicines in the US and Europe, and was recognized for its productivity and creative drug development strategies. Prior to its acquisition by GSK for $5.1

Science 52

Science Regulations Production Drug Development 52

FDA Law Blog: Biosimilars

AUGUST 4, 2023

Because anabolic steroids are also abused to enhance athletic performance and increase muscle strength, Congress has enacted three laws regulating anabolic steroids: the Anabolic Steroid Control Acts of 1990 and 2004, and the Designer Anabolic Steroid Control Act of 2014 (“DASCA”). DASCA became law, amending the CSA, on December 18, 2014.

Regulations 52

Regulations Production Drugs Clinical Trials 52

The Pharma Data

SEPTEMBER 18, 2020

Despite the drug’s own warnings, Janssen marketed the drug as having fewer addictive qualities than competitors, citing various different studies and data. One of their primary data sources was the Drug Abuse Warning Network (DAWN). Janssen continued the misleading practice of understating the risk of addiction. .

Marketing 52

Marketing FDA Engineering Drugs 52

Drug Target Review

JUNE 19, 2024

Mr Culley served from 2007 to 2010 as Mast’s Chief Business Officer and Senior Vice President, from 2006 to 2007 as Mast’s Senior Vice President, Business Development, and from 2004 to 2006 as Mast’s Vice President, Business Development. From 2002 until 2004, Mr Culley was Director of Business Development and Marketing for Immusol, Inc.

Therapies 84

Therapies Small Molecule Pharmaceutical Companies Molecular Biology 84

FDA Law Blog: Biosimilars

APRIL 22, 2024

Houck — Administrator Anne Milgram has been on the receiving end of high-level support for and against rescheduling marijuana since the Food and Drug Administration (“FDA”) and Health and Human Services (“HHS”) recommended the Drug Enforcement Administration (“DEA”) reschedule from schedule I to schedule III last August.

FDA 59

FDA Drugs International 59

Sygnature Discovery

NOVEMBER 2, 2023

High-fidelity hit finding is a critical initiation step in any successful drug discovery project and is increasingly important as new drug targets become harder to prosecute. This significant investment forms part of the company’s longer-term vision for leading the drug discovery market in hit-finding capabilities.

Science 52

Science Disease Drugs Marketing 52

Sygnature Discovery

SEPTEMBER 14, 2023

Sygnature Discovery is delighted to announce that its customer, River BioMedics , has raised an additional €2M in seed funding to continue its life-saving cardiovascular drug research. The two companies have collaborated in cardiovascular drug discovery since March 2021.

Small Molecule 52

Small Molecule Assay Development Disease Drug Research 52

The Pharma Data

SEPTEMBER 15, 2020

Find out solutions to mitigate the impact from clinical supply chain risk and discover how to improve dynamic drug supply forecasting strategies. Enrolling study subjects, setting up patient randomization and managing drug supply are critical to the success of a clinical trial. Matthew Konneh, Vice President of Strategic Alliances.

Clinical Supply 52

Clinical Supply Clinical Trials Doctors Clinical Development 52

Pharmaceutical Development Group

AUGUST 9, 2021

In contrast, the number of new drugs approved and accepted in the marketplace has dropped to an all-time low. Biotechnology and genomics businesses were projected to perform around one-fifth of all pharmaceutical research and development in 2004. (R&D). So design quality is linked to product performance.

Pharmaceuticals 52

Pharmaceuticals Pharmaceutical Companies FDA Approval Production 52

Sygnature Discovery

SEPTEMBER 25, 2023

About Sygnature Discovery Sygnature Discovery is a world-leading integrated drug discovery Contract Research Organisation based in the UK and Canada with its headquarters in Nottingham and additional sites in Alderley Park, Macclesfield, Glasgow, Montreal and Quebec City.

Targeted Protein Degradation 52

Targeted Protein Degradation Small Molecule Science Disease 52

Elrig

SEPTEMBER 13, 2024

From the 1stof September 2025, Dr Laura Ajram, Chief Executive, British Neuroscience Association will join to expand and support ELRIGs partnership initiatives with other associations. I would like to personally thank Paul and Clare for their valuable contributions over the years and I am delighted to welcome Rob, Lisa and Laura.

Science 52

Science Laboratories Government Research 52

Sygnature Discovery

MARCH 24, 2022

When DMPK scientist Lynette Ongeri joined Sygnature this month, she unknowingly helped us reach a landmark we couldn’t be prouder of… Sygnature Discovery – or Sygnature Chemical Services Ltd, as it was known then – opened its doors in 2004 with five colleagues. Want to join Lynette in working at an innovative integrated drug discovery CRO?

Computational Chemistry 52

Computational Chemistry International Science Pharmaceuticals 52

The Pharma Data

DECEMBER 10, 2020

1, 2004 and Dec. The researchers linked the information to Swedish health and drug registers to identify cases of type 2 diabetes in dog and cat owners, as well as cases of diabetes and pets over a six-year follow-up period between Jan. 1, 2007 and Dec. 31, 2012.

Hospitals 52

Hospitals Disease Research Drugs 52

Sygnature Discovery

NOVEMBER 13, 2023

He brings to the board significant industry experience in both preclinical and clinical drug development as well as personal experience in developing CellCarta as a global leader in precision medicine services and within the Canadian environment. Additional sites are located in Alderley Park, Macclesfield, Glasgow, Montreal and Quebec City.

Science 52

Science Disease Pharmaceuticals Government 52

Drug Target Review

OCTOBER 17, 2024

Can you elaborate on the preclinical studies and data that led to development of drug candidates along the CD24/Siglec-10 pathway? We showed that ONC-781 can be used as a platform to develop multiple modalities, including bispecific T cell engager, antibody-drug conjugates and chimeric antigen receptor T cell (CAR-T).

Immune Response 52

Immune Response Clinical Trials Trials Therapies 52

Drug Target Review

JANUARY 9, 2024

Using human cells is advantageous as bots could be built from a patient’s own cells to perform therapeutic work without initiating an immune response or needing immunosuppressants, drugs prescribed to prevent rejection of transplanted tissues and organs which are also used in the treatment of autoimmune disorders. Immunosuppressants.

Laboratories 59

Laboratories Immune Response DNA Science 59

FDA Law Blog: Biosimilars

MAY 23, 2023

Food and Drug Administration (FDA) released a draft update to its Compliance Policy Guide (CPG) for FDA staff on the Agency’s enforcement of major food allergen labeling and cross-contact. By Sophia R. Gaulkin & Riëtte van Laack — On May 16, the U.S. Part 117, and the Food Allergy Safety, Treatment, Education and Research Act (2021).

FDA 45

FDA Compliance Regulations Production 45

The Pharma Data

NOVEMBER 8, 2020

This transaction will enhance Pharmaron’s fully integrated, end-to-end drug R&D service offerings globally. Absorption Systems is based in the USA with facilities and laboratories in Philadelphia, San Diego and Boston. Strata Partners acted as exclusive financial advisers to Pharmaron, and O’Melveny acted as legal counsel.

Clinical Pharmacology 40

Clinical Pharmacology Laboratories Science Pharmaceuticals 40

Agency IQ

JULY 13, 2023

That law built upon several other previous laws, including the Public Health Threats and Emergencies Act of 2000, the Public Health Security and Bioterrorism Preparedness and Response Act of 2002 and the Project BioShield Act of 2004 ( see a Congressional Research Service report on its legislative history here ).

FDA 40

FDA Packaging Laboratories Testimonials 40

Practical Cheminformatics

JUNE 12, 2023

The BSD is much more representative of the data encountered in drug discovery programs. Modeling Aqueous Solubility with ESOL John Delaney published one of the simpler methods for predicting aqueous solubility in 2004. Realistic, high-quality datasets are crucial to advancing the application of ML in drug discovery. Why is this?

Drugs 116

Drugs Trials 116

Agency IQ

APRIL 12, 2024

Directive 2001/83/EC and Regulation (EC) No 726/2004. Additionally, reform package included revisions of the regulations for pediatric medicines and orphan drugs. For the regulation , this centered on market exclusivity for orphan drugs and whether there should be a separate category for medicinal products addressing unmet need.

Pharmaceuticals 40

Pharmaceuticals Regulations Packaging Marketing 40

Molecular Design

JANUARY 27, 2019

by mandating that LE values be quoted when presenting project updates at the dog and pony shows that are an essential part of modern drug discovery). 15) and “the LE metric is rarely, if ever, shown to be predictive of phenomena that are relevant to drug discovery” (p. Imagine if they ran clinical trials like this? Lower deck.

Science 52

Science Clinical Trials Trials Drugs 52